Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADISE-MI: LCZ696 vs Ramipril in Post-AMI Patients
NCT02924727Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in acute myocardial infarction (AMI) (2 arms), sponsored by Novartis. Primary endpoint: Number of Participants With First CEC Confirmed Primary Composite Endpoint (CV Death, HF Hospitalization, or Outpatient HF) up to 43 months. Started Dec 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT02924727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924727.